Mannosamine-desthiobiotin adduct (compound MDTBA) is a carrier immunogenicity-reducing hapten that reduces the immunogenicity of protein carriers upon conjugation to available free amines on the carrier protein surface. Conjugation of Mannosamine-desthiobiotin adduct to hsIgG significantly (>1-fold) reduced the immunogenicity of hsIgG. Mannosamine-desthiobiotin adduct can be used in antigen design research[1].

Mannosamine-lipoic acid adduct is a hapten. Mannosamine-lipoic acid adduct with hsIgG conjugation significantly reduces the antibody immune response against hsIgG[1].

Mansonone F is a potent anti-MRSA sesquiterpenoid quinone that can be found in Thespesia populnea[1].

Mant-GTPγS triammonium, a GTP mimetic, is a potent competitive adenylyl cyclase (AC) inhibitor. Mant-GTPγS triammonium is a potent YdeH inhibitor[1][2][3].

Manusiran sodium is a potent TMPRSS6 (transmembrane protease serine 6) synthesis reducer[1].

Manwuweizic acid is a triterpenoid that can be isolated from Kadsura heteroclite[1].

Manwuweizic acid is a triterpenoid that can be isolated from Kadsura heteroclite[1].

MAO A/HSP90-IN-1 (4-b) is a MAO A/HSP90 dual inhibitor with IC50 value of 1.77 μM and 0.019 μM in Glioblastoma (GBM) GL26 cells and HSP90α, respectively. MAO A/HSP90-IN-1 (4-b) can inhibit MAO A activity, HSP90 binding and the expression of HER2 and phospho-Akt to inhibit the growth of GBM, they also reduce PD-L1 expression, which […]

MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, […]

MAO-A inhibitor 1 (compound VIII) is a MAO-A inhibitor, with an IC50 of 100 μM[1].

MAO-B-IN-18 is a potent and selective MAO B inhibitor with IC50s of 52 nM and 14 μM for hMAO B and hMAO A, respectively. MAO-B-IN-18 enables promising cytoprotective effects against hydrogen peroxide insults in neuroblastoma and astrocytes cultures[1].

MAO-B-IN-18 is a potent and selective MAO B inhibitor with IC50s of 52 nM and 14 μM for hMAO B and hMAO A, respectively. MAO-B-IN-18 enables promising cytoprotective effects against hydrogen peroxide insults in neuroblastoma and astrocytes cultures[1].

MAO-B-IN-18 is a potent and selective MAO B inhibitor with IC50s of 52 nM and 14 μM for hMAO B and hMAO A, respectively. MAO-B-IN-18 enables promising cytoprotective effects against hydrogen peroxide insults in neuroblastoma and astrocytes cultures[1].

MAO-B-IN-18 is a potent and selective MAO B inhibitor with IC50s of 52 nM and 14 μM for hMAO B and hMAO A, respectively. MAO-B-IN-18 enables promising cytoprotective effects against hydrogen peroxide insults in neuroblastoma and astrocytes cultures[1].

MAO-B-IN-19 is a selective MAO-B inhibitor with an IC50 of 0.67 μM. MAO-B-IN-19 shows neuroprotective and anti-inflammatory properties[1].

MAO-B-IN-20 (Compound C14) is a potent MAO-B inhibitor with an IC50 of 0.037 μM. MAO-B-IN-20 displays good metabolic stability and brain-blood barrier permeability. MAO-B-IN-20 can be used for the research of Parkinson’s disease[1].

MAO-B-IN-21 is an excellent MAO-B inhibitor with antioxidant activity and anti-Aβ aggregation activity. MAO-B-IN-21 also exhibits metal-ion chelating ability, anti-neuroinflammation (NO, TNF-α), neuroprotective activity and BBB permeability. MAO-B-IN-21 significantly improves the memory and cognitive impairment in Aβ1-42 induced Alzheimer’s disease mice model[1].

MAO-B-IN-22 (compound 6h) is a potent MAO-B inhibitor with an IC50 of 0.014 μM. MAO-B-IN-22 has high antioxidant activity, good metal chelating ability, proper BBB permeability and significant neuroprotective effect[1].

MAO-B-IN-23 (Compound 11f) is a reversible and competitive MAO-B inhibitor (IC50: 1.44 μM, Ki: 0.51 μM)[1].

MAO-B-IN-24 (compound 11h) is a selective, reversible, competitive inhibitor of MAO-B (IC50: 1.60 μM). MAO-B-IN-24 also inhibited MAO-A (22.42 μM); at 10 μM concentration, it also reduced AChE and BChE activities to 54.58% and 88.43%[1].

MAO-B-IN-25 (compound 92) is a selective MAO-B inhibitor with IC50s of 0.5 nM and 240 nM for MAO-A and MAO-B, respectively[1].

MAO-B-IN-26 (Compound IC9) is a MAO-B and acetylcholinesterase inhibitor. MAO-B-IN-26 protects SH?SY5Y cells against Aβ induced cytotoxicity, morphological changes, ROS generation and membrane damage. MAO-B-IN-26 also inhibits Aβ induced autophagy and apoptosis. MAO-B-IN-26 can be used as a neuroprotective agent against Alzheimer’s disease[1].

MAO-B-IN-27 (Compound 12c) is a monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-27 has potent and selective MAO-B inhibitory effect for hMAO-B with an IC50 values of 8.9 nM. MAO-B-IN-27 can be used for the research of parkinson’s disease (PD)[1].

MAO-B-IN-28 (compound 10e) is a potent hMAO-B inhibitor with an IC50 of 1.9±0.5 nM. MAO-B-IN-28 can be used as a candidate for neurodegenerative diseases research[1].

MAO-B-IN-29 (compound 9a) is a inhibitor against MAO-B activity[1].

MAO-B-IN-3 is a reversible and selective MAO-B inhibitor (IC50=96 nM). MAO-B-IN-3 also binds to 5-HT6R with Ki value of 696 nM. MAO-B-IN-3 can be used for research of in Alzheimer’s disease[1].

MAO-B-IN-4 (Compound 26) is an orally active and reversible MAO-B inhibitor with an IC50 of 9 nM. MAO-B-IN-4 has good metabolic stability, safety profile and brain permeability. MAO-B-IN-4 shows antidepressant activity in rats and mice. MAO-B-IN-4 can be used in studies related to Alzheimer’s disease[1].

MAO-IN-3 (Compound 5) is a reversible and competitive MAO inhibitor (Ki: 0.6 and 0.2 μM for MAO A and MAO B). MAO-IN-3 inhibits LN-229 glioblastoma cell proliferation with an IC50 of 0.8 μM. MAO-IN-3 can be used for cancer research[1].

MAOA-IN-1 (compound 15) is an orally active MAOA inhibitor with cytotoxicity against prostate cancer cells. MAOA-IN-1 has Caco-2 permeability and lower CNS permeability. MAOA-IN-1 can be further used in the research of anti-cancer and anti-inflammatory indications[1].

MAOS is a modified Trinder’s reagent that can be used as a chromogenic probe for the determination of H2O2. MAOS is strongly dependent on the pH of the reaction medium[1].

MAOS is a modified Trinder’s reagent that can be used as a chromogenic probe for the determination of H2O2. MAOS is strongly dependent on the pH of the reaction medium[1].

MAP17 (Cell-penetrating peptide MAP17) is a synthetic secondary amphipathic cell-penetrating peptides, with sequence of QLALQLALQALQAALQLA[1].

MAP2 Antibody is an unconjugated, approximately 60 kDa, rabbit-derived, anti-MAP2 polyclonal antibody. MAP2 Antibody can be used for: WB, IF-Cell, IHC-P expriments in human, mouse, rat background without labeling.

MAP2 Antibody is an unconjugated, approximately 60 kDa, rabbit-derived, anti-MAP2 polyclonal antibody. MAP2 Antibody can be used for: WB, IF-Cell, IHC-P expriments in human, mouse, rat background without labeling.

MAP2 Antibody is an unconjugated, approximately 60 kDa, rabbit-derived, anti-MAP2 polyclonal antibody. MAP2 Antibody can be used for: WB, IF-Cell, IHC-P expriments in human, mouse, rat background without labeling.

Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer[1].

MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity. MAPK-IN-2 inhibits cancer cell proliferation among serval cancer cell lines, and suppresses MAPK pathway with potant efficacy (EGFRWT IC50=281 nM, c-MET IC50=205 nM, B-RAFWT IC50=112 nM, and CDK4/6 IC50=95 and 184 nM, respectively). MAPK-IN-2 even shows a remarkable potency against mutated EGFR and B-RAF […]

MAPK14 Antibody is a non-conjugated and Mouse origined monoclonal antibody about 41 kDa, targeting to MAPK14. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Human, Mouse.

MAPK14 Antibody is a non-conjugated and Mouse origined monoclonal antibody about 41 kDa, targeting to MAPK14. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Human, Mouse.

MAPK14 Antibody is a non-conjugated and Mouse origined monoclonal antibody about 41 kDa, targeting to MAPK14. It can be used for WB,ICC,IHC-P assays with tag free, in the background of Human, Mouse.

MAPKAP Kinase 2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 46 kDa, targeting to MAPKAP Kinase 2. It can be used for WB,IP assays with tag free, in the background of Human, Mouse.

MAPKAP Kinase 2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 46 kDa, targeting to MAPKAP Kinase 2. It can be used for WB,IP assays with tag free, in the background of Human, Mouse.

MAPKAP Kinase 2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 46 kDa, targeting to MAPKAP Kinase 2. It can be used for WB,IP assays with tag free, in the background of Human, Mouse.

Maprotiline (hydrochloride) (Standard) is the analytical standard of Maprotiline (hydrochloride). This product is intended for research and analytical applications.

Maprotiline (hydrochloride) (Standard) is the analytical standard of Maprotiline (hydrochloride). This product is intended for research and analytical applications.

Maprotiline (hydrochloride) (Standard) is the analytical standard of Maprotiline (hydrochloride). This product is intended for research and analytical applications.

MAQAAEYYR is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MAQAAEYYR has high DPPH and ABTS radical scavenging ability. MAQAAEYYR protects zebrafish larvae from H2O2-induced oxidative damage[1].

MAQAAEYYR TFA is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MAQAAEYYR TFA has high DPPH and ABTS radical scavenging ability. MAQAAEYYR TFA protects zebrafish larvae from H2O2-induced oxidative damage[1].

Margatoxin TFA, an alpha-KTx scorpion toxin, is a high affinity inhibitor of Kv1.3 (Kd=11.7 pM). Margatoxin TFA inhibits the Kv1.2 (Kd=6.4 pM) and Kv1.1 (Kd=4.2 nM). Margatoxin TFA, a 39 amino-acid-long peptide, is isolated from the venom of the scorpion Centruroides margaritatus and widely used in ion channel research[1][2].

Maridebart is a humanized immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody[1].